Loading
  • Pipeline Pipeline
    • Pipeline Chart
    • ALXN1840
      • EASL Poster May 2025
    • uPAR-targeted radiopharmaceuticals
    • MNPR-101
      • Overview
      • Development Strategy
      • SNMMI Poster June 2024
      • EANM Presentation October 2024
    • Collaborations
      • Overview
      • Current Collaborations
    • Publications
      • MNPR-101
  • Investors Investors
    • Overview
    • Annual Meeting
    • News / Events
      • Press Releases
      • IR Calendar
      • In the News
      • Email Alerts
    • Company Information
      • Profile
      • Presentations
      • Our Team
      • FAQ
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Our Team Our Team
  • Careers Careers
  • Contact Us Contact Us
  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Investors

  • Overview
  • Annual Meeting
  • News / Events
    • Press Releases
    • IR Calendar
    • In the News
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Our Team
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Press Releases
  • IR Calendar
  • In the News
  • Email Alerts

Press Releases

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

Aug 12, 2025

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Jun 11, 2025

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 3, 2025

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 13, 2025

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Apr 29, 2025

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Mar 31, 2025

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Dec 20, 2024

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Dec 5, 2024

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Dec 3, 2024
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...12
  • About
  • Pipeline
  • Investors
  • Our Team
  • Careers
  • Contact Us
  • Pipeline
  • Pipeline Chart
  • ALXN1840
  • uPAR-targeted radiopharmaceuticals
  • MNPR-101
  • Collaborations
  • Publications
  • Investors
  • Overview
  • Annual Meeting
  • News / Events
  • Company Information
  • Stock Data
  • SEC Filings
  • Corporate Governance

Terms and Conditions of Use

© 2025 Monopar Therapeutics Inc. All Rights Reserved.